Page last updated: 2024-10-31

modafinil and Apnea, Obstructive Sleep

modafinil has been researched along with Apnea, Obstructive Sleep in 62 studies

Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.

Research Excerpts

ExcerptRelevanceReference
"In 2010 the European Medicines Agency withdrew the indication of modafinil for the treatment of obstructive sleep apnea, shift work sleep disorder and for idiopathic hypersomnia (IH)."9.20Modafinil in the treatment of idiopathic hypersomnia without long sleep time--a randomized, double-blind, placebo-controlled study. ( Benes, H; Bitterlich, M; Mayer, G; Rodenbeck, A; Young, P, 2015)
"We aimed to evaluate the efficacy of the selective H3 receptor inverse agonist MK-0249 to treat excessive daytime sleepiness (EDS)."9.17Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study. ( Ceesay, P; Herring, WJ; Hutzelmann, J; Lines, C; Liu, K; Michelson, D; Roth, T; Snavely, D; Snyder, E, 2013)
"Once-daily modafinil was effective and well tolerated for managing residual daytime sleepiness in Japanese OSAS patients with residual excessive daytime sleepiness on optimal nCPAP therapy."9.17Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study. ( Inoue, Y; Takasaki, Y; Yamashiro, Y, 2013)
"Armodafinil-naïve, adult patients with excessive sleepiness associated with treated OSA (n = 170), SWD (n = 108), or narcolepsy (n = 50) received armodafinil (100-250 mg) once daily (treated OSA or narcolepsy) or before night shifts (SWD)."9.14Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. ( Khan, A; McCall, WV; Schwartz, JR; Tiller, J; Weintraub, J, 2010)
"Patients with ES associated with treated OSA, SWD, or narcolepsy who completed one of four 12-week, double-blind studies were eligible for this multicenter, open-label study of > or = 12 months' duration of treatment with armodafinil (50 to 250 mg/day)."9.14The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. ( Black, JE; Harsh, JR; Hull, SG; Tiller, J; Yang, R, 2010)
"The results of this indirect treatment comparison show 12 weeks of treatment with solriamfetol, modafinil, and armodafinil resulted in varying levels of improvement on the ESS, MWT20, and CGI-C and similar safety risks in participants with excessive daytime sleepiness associated with obstructive sleep apnea."9.12Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea. ( Bron, M; Bujanover, S; Kratochvil, D; Lucas, E; Menno, D; Patel, D; Ronnebaum, S; Stepnowsky, C, 2021)
"Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure."8.84Modafinil in the treatment of excessive daytime sleepiness. ( Foldvary-Schaefer, N; Valentino, RM, 2007)
"Modafinil is a wake-promoting drug licensed to treat residual sleepiness in CPAP-treated OSA."6.79Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial. ( Chang, CL; Chapman, JL; Grunstein, RR; Kempler, L; Marshall, NS; Sivam, S; Williams, SC; Wong, KK; Yee, BJ, 2014)
"Solriamfetol, armodafinil-modafinil, and pitolisant reduce daytime sleepiness for patients with OSA already on conventional therapy, with solriamfetol likely superior."5.41Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis. ( Busse, JW; Desai, K; Gu, Y; Mah, J; Pitre, T; Roberts, S; Ryan, C; Zeraatkar, D, 2023)
"In 2010 the European Medicines Agency withdrew the indication of modafinil for the treatment of obstructive sleep apnea, shift work sleep disorder and for idiopathic hypersomnia (IH)."5.20Modafinil in the treatment of idiopathic hypersomnia without long sleep time--a randomized, double-blind, placebo-controlled study. ( Benes, H; Bitterlich, M; Mayer, G; Rodenbeck, A; Young, P, 2015)
"We aimed to evaluate the efficacy of the selective H3 receptor inverse agonist MK-0249 to treat excessive daytime sleepiness (EDS)."5.17Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study. ( Ceesay, P; Herring, WJ; Hutzelmann, J; Lines, C; Liu, K; Michelson, D; Roth, T; Snavely, D; Snyder, E, 2013)
"Once-daily modafinil was effective and well tolerated for managing residual daytime sleepiness in Japanese OSAS patients with residual excessive daytime sleepiness on optimal nCPAP therapy."5.17Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study. ( Inoue, Y; Takasaki, Y; Yamashiro, Y, 2013)
"Sodium oxybate (SXB) is approved for cataplexy and excessive daytime sleepiness in narcolepsy."5.15A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome. ( Feldman, N; George, CF; Grzeschik, SM; Inhaber, N; Lai, C; Steininger, TL; Zheng, Y, 2011)
"Armodafinil-naïve, adult patients with excessive sleepiness associated with treated OSA (n = 170), SWD (n = 108), or narcolepsy (n = 50) received armodafinil (100-250 mg) once daily (treated OSA or narcolepsy) or before night shifts (SWD)."5.14Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. ( Khan, A; McCall, WV; Schwartz, JR; Tiller, J; Weintraub, J, 2010)
"Sodium oxybate (SXB) is an approved drug for the treatment of excessive daytime sleepiness (EDS) and cataplexy in narcolepsy."5.14A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing. ( Feldman, N; George, CF; Grzeschik, SM; Inhaber, N; Lai, C; Steininger, TL; Zheng, Y, 2010)
"Prospective evaluation of unselected traumatic brain injury patients with nocturnal polysomnography (NPSG), multiple sleep latency test (MSLT), Epworth Sleepiness Scale (ESS), and neuropsychological testing including Psychomotor Vigilance Test (PVT), Profile of Mood States (POMS), and Functional Outcome of Sleep Questionnaire (FOSQ) before and after treatment with continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA), modafinil (200 mg) for narcolepsy and posttraumatic hypersomnia (PTH), or pramipexole (0."5.14Treatment of sleep disorders after traumatic brain injury. ( Atanasov, S; Castriotta, RJ; Kuna, ST; Lai, JM; Masel, BE; Wilde, MC, 2009)
"Patients with ES associated with treated OSA, SWD, or narcolepsy who completed one of four 12-week, double-blind studies were eligible for this multicenter, open-label study of > or = 12 months' duration of treatment with armodafinil (50 to 250 mg/day)."5.14The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. ( Black, JE; Harsh, JR; Hull, SG; Tiller, J; Yang, R, 2010)
"In summary, our study confirms that modafinil used adjunctively with CPAP therapy improves subjective daytime sleepiness in patients with OSAS who were regular users of CPAP therapy but still experienced sleepiness."5.13Placebo and modafinil effect on sleepiness in obstructive sleep apnea. ( Bittencourt, LR; Garbuio, SA; Guilleminault, C; Lucchesi, LM; Palombini, LO; Rueda, AD; Tufik, S, 2008)
"The results of this indirect treatment comparison show 12 weeks of treatment with solriamfetol, modafinil, and armodafinil resulted in varying levels of improvement on the ESS, MWT20, and CGI-C and similar safety risks in participants with excessive daytime sleepiness associated with obstructive sleep apnea."5.12Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea. ( Bron, M; Bujanover, S; Kratochvil, D; Lucas, E; Menno, D; Patel, D; Ronnebaum, S; Stepnowsky, C, 2021)
"Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure."4.84Modafinil in the treatment of excessive daytime sleepiness. ( Foldvary-Schaefer, N; Valentino, RM, 2007)
"Armodafinil is a wake-promoting agent developed by Cephalon that was approved in mid-2007 for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder."4.84Armodafinil: a new treatment for excessive sleepiness. ( Lankford, DA, 2008)
" Treatment with continuous positive airway pressure (CPAP) for OSA, non-invasive ventilation (NIV) for respiratory failure, modafinil for excessive daytime sleepiness were commenced."3.83Sleepiness and Sleep-related Breathing Disorders in Myotonic Dystrophy and Responses to Treatment: A Prospective Cohort Study. ( Anderson, KN; Atalaia, A; Baudouin, SV; Hughes, J; Lochmüller, H; Marini-Bettolo, C; West, SD, 2016)
"Excessive daytime sleepiness (EDS) is a common consequence of OSA and is associated with cognitive deficits and anxiety."3.30Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA. ( Badran, M; Barrow, MB; Gozal, D; Puech, C; Runion, AR, 2023)
"102 patients with the diagnosis of obstructive sleep apnea (OSA) were randomized to receive either 200 mg of modafinil or placebo before general anesthesia."2.87A double blind randomized placebo controlled pilot study of single-dose preoperative modafinil for functional recovery after general anesthesia in patients with obstructive sleep apnea. ( Carr, ZJ; Karamchandani, K; Kunselman, AA; Lowery, JD; Rogers, AM; Vaida, SJ; Vells, B; Wood, BR, 2018)
"Armodafinil was generally well tolerated."2.79Effect of armodafinil on cortical activity and working memory in patients with residual excessive sleepiness associated with CPAP-Treated OSA: a multicenter fMRI study. ( Diaz, MT; Drummond, SP; Duntley, SP; Greve, DN; Krystal, AD; Kushida, CA; Larson-Prior, L; Thein, SG; Thomas, RJ; Yang, R, 2014)
"Modafinil is a wake-promoting drug licensed to treat residual sleepiness in CPAP-treated OSA."2.79Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial. ( Chang, CL; Chapman, JL; Grunstein, RR; Kempler, L; Marshall, NS; Sivam, S; Williams, SC; Wong, KK; Yee, BJ, 2014)
"Armodafinil was found to improve simulated driving performance in OSA patients with EDS prior to initiation of CPAP."2.78Effects of armodafinil on simulated driving and self-report measures in obstructive sleep apnea patients prior to treatment with continuous positive airway pressure. ( Feldman, N; Kay, GG, 2013)
" In addition, the ratios and associated 90% CIs for Cmax (137 [1."2.75Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. ( D'Andrea, DM; Darwish, M; Hellriegel, ET; Kirby, M; Robertson, P; Yang, R, 2010)
"Armodafinil was well tolerated."2.73Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. ( Arora, S; Black, JE; Hirshkowitz, M; Niebler, G; Roth, T; Wesnes, K, 2007)
"Modafinil was well tolerated."2.73Effect of adjunctive modafinil on wakefulness and quality of life in patients with excessive sleepiness-associated obstructive sleep apnoea/hypopnoea syndrome: a 12-month, open-label extension study. ( Black, J; Hirshkowitz, M, 2007)
"Daytime symptoms resulting from obstructive sleep apnea (OSA) include impaired neurobehavioural performance and increased sleepiness."2.73The effect of modafinil following acute CPAP withdrawal: a preliminary study. ( Grunstein, RR; Leung, S; Marshall, NS; Rogers, NL; Starmer, GA; Williams, SC, 2008)
"Many patients with obstructive sleep apnea (OSA) experience excessive daytime sleepiness (EDS), which can negatively affect daily functioning, cognition, mood, and other aspects of well-being."2.72Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management. ( Bae, CJ; Lal, C; Strohl, KP; Weaver, TE, 2021)
"Armodafinil was also associated with significantly reduced interference of ES with daily activities and global fatigue."2.72Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. ( Arora, S; Black, J; Niebler, G; Roth, T; Schmidt-Nowara, W; Wesnes, KA; White, D, 2006)
"Some patients with obstructive sleep apnea/hypopnea syndrome (OSA/HS) who are regular users of nasal continuous positive airway pressure (nCPAP) therapy continue to experience daytime sleepiness that impairs performance and quality of life."2.71Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. ( Dinges, DF; Weaver, TE, 2003)
"Modafinil remained effective and well tolerated as an adjunct therapy for residual daytime sleepiness even after 12 weeks of daily dosing in patients with OSA receiving nCPAP therapy."2.71Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. ( Erman, MK; Hirshkowitz, M; Schmidt-Nowara, W; Schwartz, JR, 2003)
"Modafinil was generally well tolerated and did not adversely affect nighttime sleep or nCPAP use."2.71Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. ( Black, JE; Hirshkowitz, M, 2005)
"Patients with obstructive sleep apnea/hypopnea syndrome can experience residual daytime sleepiness despite regular use of nasal continuous positive airway pressure therapy."2.70Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. ( Black, JE; Matheson, JK; Pack, AI; Schwartz, JR, 2001)
"Modafinil is a nonamphetamine nootropic drug with an increasingly therapeutic interest due to its different sites of action and behavioral effects in comparison to cocaine or amphetamine."2.66Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. ( Dinis-Oliveira, RJ; Sousa, A, 2020)
"Collapsibility of the upper airway in obstructive sleep apnea (OSA) causes repeated arousals from sleep, decreased oxygen saturation of the blood, and excessive sleepiness (ES)."2.45Optimal treatment of obstructive sleep apnea and excessive sleepiness. ( Doghramji, P; Rosenberg, R, 2009)
"Clinical trials in these sleep disorders demonstrated an enhanced efficacy for wake promotion (wake sustained for a longer time period using doses lower than those of modafinil)."2.44Armodafinil for excessive daytime sleepiness. ( Nishino, S; Okuro, M, 2008)
"Modafinil also has the potential for interactions with other drugs metabolised via cytochrome P450 enzyme pathways."2.43Modafinil: new indications for wake promotion. ( Schwartz, JR, 2005)
"Modafinil (Provigil is a wake-promoting agent that is pharmacologically distinct from CNS stimulants, such as amfetamine, dexamfetamine and methylphenidate."2.43Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. ( Keating, GM; Raffin, MJ, 2005)
"A significant number of patients with obstructive sleep apnea neither tolerate positive airway pressure (PAP) therapy nor achieve successful outcomes from either upper airway surgeries or use of an oral appliance."2.43Medical therapy for obstructive sleep apnea: a review by the Medical Therapy for Obstructive Sleep Apnea Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. ( Ballard, RD; Guilleminault, C; Magalang, UJ; Sanders, MH; Strohl, KP; Veasey, SC, 2006)
"OSA can induce excessive daytime sleepiness (EDS) and is associated with impaired cognition and anxiety."1.91Recovery Mimicking "Ideal" CPAP Adherence Does Not Improve Wakefulness or Cognition in Chronic Murine Models of OSA: Effect of Wake-Promoting Agents. ( Badran, M; Barrow, MB; Gozal, D; Puech, C; Runion, AR, 2023)
"BACKGROUND Obstructive sleep apnea-hypopnea syndrome (OSAHS) is characterized by repeated episodes of reduction in airflow due to the collapse of the upper airway during sleep."1.48Comparison of the Efficacy, Side Effects, and Cost of Modafinil and Intranasal Mometasone Furoate in Obstructive Sleep Apnea-Hypopnea Syndrome: A Preliminary Clinical Study. ( Duan, Z; Fu, J; Zhang, S, 2018)
"In modafinil-treated patients, clinically significant increases in diastolic or systolic blood pressure were infrequent (n = 9 and n = 1, respectively, < 1% of patients)."1.34Evaluation of the safety of modafinil for treatment of excessive sleepiness. ( Arora, S; Dayno, JM; Erman, MK; Hirshkowitz, M; Roth, T; Schwartz, JR, 2007)

Research

Studies (62)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's29 (46.77)29.6817
2010's23 (37.10)24.3611
2020's10 (16.13)2.80

Authors

AuthorsStudies
Puech, C3
Badran, M3
Barrow, MB3
Runion, AR3
Gozal, D3
Pitre, T1
Mah, J1
Roberts, S1
Desai, K1
Gu, Y1
Ryan, C1
Busse, JW1
Zeraatkar, D1
Sousa, A1
Dinis-Oliveira, RJ1
Lin, YC1
Chen, TY1
Chien, WC1
Chung, CH1
Chang, HA1
Kao, YC1
Tsai, CS1
Lin, CS1
Tzeng, NS1
Javaheri, S2
Lal, C1
Weaver, TE3
Bae, CJ1
Strohl, KP2
Ronnebaum, S1
Bron, M1
Patel, D1
Menno, D1
Bujanover, S1
Kratochvil, D1
Lucas, E1
Stepnowsky, C1
Krief, S1
Berrebi-Bertrand, I1
Nagmar, I1
Giret, M1
Belliard, S1
Perrin, D1
Uguen, M1
Robert, P1
Lecomte, JM1
Schwartz, JC1
Finance, O1
Ligneau, X1
Zhang, S1
Fu, J1
Duan, Z1
Carr, ZJ1
Vells, B1
Wood, BR1
Lowery, JD1
Rogers, AM1
Kunselman, AA1
Karamchandani, K1
Vaida, SJ1
Kay, GG1
Feldman, N3
Herring, WJ1
Liu, K1
Hutzelmann, J1
Snavely, D1
Snyder, E1
Ceesay, P1
Lines, C1
Michelson, D1
Roth, T5
Inoue, Y1
Takasaki, Y1
Yamashiro, Y1
Launois, SH1
Tamisier, R1
Lévy, P1
Pépin, JL1
Chapman, JL2
Kempler, L1
Chang, CL1
Williams, SC3
Sivam, S1
Wong, KK1
Yee, BJ2
Grunstein, RR3
Marshall, NS4
Greve, DN1
Duntley, SP1
Larson-Prior, L1
Krystal, AD1
Diaz, MT1
Drummond, SP1
Thein, SG1
Kushida, CA1
Yang, R3
Thomas, RJ1
Mayer, G1
Benes, H1
Young, P1
Bitterlich, M1
Rodenbeck, A1
Sukhal, S1
Khalid, M1
Tulaimat, A1
Wang, D1
Bai, XX1
Hua, SC1
Kim, JW1
D'Rozario, A1
Vakulin, A1
Hedner, J1
Kuan, YC1
Wu, D1
Huang, KW1
Chi, NF1
Hu, CJ1
Chung, CC1
Tam, KW1
Huang, YH1
West, SD1
Lochmüller, H1
Hughes, J1
Atalaia, A1
Marini-Bettolo, C1
Baudouin, SV1
Anderson, KN1
Nishino, S1
Okuro, M1
Ballard, RD2
Rosenberg, R1
Doghramji, P1
Garnock-Jones, KP1
Dhillon, S1
Scott, LJ1
George, CF2
Inhaber, N2
Steininger, TL2
Grzeschik, SM2
Lai, C2
Zheng, Y2
Castriotta, RJ1
Atanasov, S1
Wilde, MC1
Masel, BE1
Lai, JM1
Kuna, ST1
Chasens, ER1
Arora, S5
Black, W1
Hoey, P1
Mayze, T1
Dopp, JM1
Morgan, BJ1
Schwartz, JR5
Khan, A1
McCall, WV1
Weintraub, J1
Tiller, J2
Black, JE4
Hull, SG1
Harsh, JR1
Darwish, M1
Kirby, M1
D'Andrea, DM1
Hellriegel, ET1
Robertson, P1
Andrade, C1
Black, J3
Ault, A1
Dinges, DF1
Hirshkowitz, M5
Erman, MK2
Schmidt-Nowara, W2
Douglas, NJ1
Lieberman, JA1
Keating, GM1
Raffin, MJ1
White, D1
Wesnes, KA1
Niebler, G2
Wesnes, K1
Veasey, SC1
Guilleminault, C2
Sanders, MH1
Magalang, UJ1
Carl, D1
Sica, DA1
Valentino, RM1
Foldvary-Schaefer, N1
Rippon, GA1
Nikolaou, A1
Schiza, SE1
Giakoumaki, SG1
Roussos, P1
Siafakas, N1
Bitsios, P1
Dayno, JM1
Bittencourt, LR1
Lucchesi, LM1
Rueda, AD1
Garbuio, SA1
Palombini, LO1
Tufik, S1
Rogers, NL1
Leung, S1
Starmer, GA1
Lankford, DA1
Pack, AI1
Matheson, JK1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase IIa, Randomized, Double-blind, Placebo-controlled, 3-period Crossover, Adaptive Dose Design, Clinical Trial to Evaluate Safety & Efficacy of MK0249 in Treating Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea[NCT00620659]Phase 2125 participants (Actual)Interventional2008-02-29Terminated
Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of Armodafinil (200 mg/Day) on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea[NCT00711516]Phase 440 participants (Actual)Interventional2008-09-30Completed
Improvement in Sleep Symptomatology and Neurocognitive Function Using Photobiomodulation in Post-Concussion Patients With Sleep-Wake Disturbances[NCT05072743]20 participants (Anticipated)Interventional2021-10-20Recruiting
A Randomized, Double Blind, Placebo Controlled Evaluation of Modafinil vs Placebo for the Treatment of General Anesthesia Related Delayed Emergence in Patients With the Diagnosis of Obstructive Sleep Apnea[NCT02494102]Phase 4105 participants (Actual)Interventional2016-02-29Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clinical Global Impressions Scale of Severity Score as it Relates to Excessive Daytime Sleepiness (CGIS-EDS) for the Mode Dose of MK0249 Versus Placebo

Clinical Global Impressions Scale of Severity (CGI-S) is a subscale of the CGI which is a standard psychometric scale used to demonstrate changes and improvements in illness. CGI-S consists of a 7-point scale rated from 1 to 7. The investigator or sponsor-approved clinician judged how ill the patient was with respect to Excessive Daytime Sleepiness (EDS) at the time of the CGI-S rating (CGIS-EDS), with higher scores indicating more severe illness. (NCT00620659)
Timeframe: At Week 2

Interventionunits on a scale (Least Squares Mean)
Placebo3.76
MK0249 Mode Dose3.43

Epworth Sleepiness Scale (ESS) Score for the Mode Dose of MK0249 Versus Placebo

"The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire that provides subjective reports that equate with sleep propensity, not with 'subjective sleepiness'. Having a high sleep propensity means having a history of dozing in situations that have a relatively low soporific nature, in which normal subjects seldom doze. The ESS consists of eight items, which are rated from 0 (would never dose) to 3 (high chance of dozing). The ESS score is the total score of the 8 individual items; this total score ranges from 0 to 24 (higher total score is worse)." (NCT00620659)
Timeframe: At Week 2

Interventionunits on a scale (Least Squares Mean)
Placebo12.81
MK0249 Mode Dose10.83

Mean of Average Maintenance of Wakefulness Test Early for the Mode Dose of MK0249 Versus Modafinil

The Maintenance of Wakefulness Test (MWT) is an objective assessment of sleepiness that measures the ability of a patient to remain awake. The primary endpoint was the mean of sleep latency (average of the first 4 MWTs which were at 0900, 1100, 1300, and 1500), where latency for each MWT was defined as the time to onset of the first 16 continuous seconds of any stage of sleep; if no sleep was observed according to these rules, then latency was defined as 30 minutes. The comparison was for the mode dose of MK0249 versus modafinil. (NCT00620659)
Timeframe: At Week 2

InterventionMinutes (Least Squares Mean)
MK0249 Mode Dose13.34
Modafinil 200 mg17.45

Mean of Average Maintenance of Wakefulness Test Early for The Mode Dose of MK0249 Versus Placebo

The Maintenance of Wakefulness Test (MWT) is an objective assessment of sleepiness that measures the ability of a patient to remain awake. The primary endpoint was the mean of sleep latency (average of the first 4 MWTs which were at 0900, 1100, 1300, and 1500), where latency for each MWT was defined as the time to onset of the first 16 continuous seconds of any stage of sleep; if no sleep was observed according to these rules, then latency was defined as 30 minutes. The comparison was for the mode dose of MK0249 versus placebo. (NCT00620659)
Timeframe: At Week 2

InterventionMinutes (Least Squares Mean)
Placebo12.79
MK0249 Mode Dose13.34

Mean of Average Maintenance of Wakefulness Test Early for Top 2 Doses Pooled of MK0249 Versus Modafinil

The Maintenance of Wakefulness Test (MWT) is an objective assessment of sleepiness that measures the ability of a patient to remain awake. The primary endpoint was the mean of sleep latency (average of the first 4 MWTs which were at 0900, 1100, 1300, and 1500), where latency for each MWT was defined as the time to onset of the first 16 continuous seconds of any stage of sleep; if no sleep was observed according to these rules, then latency was defined as 30 minutes. The comparison was for the top 2 doses pooled of MK0249 versus modafinil. (NCT00620659)
Timeframe: At Week 2

InterventionMinutes (Least Squares Mean)
MK0249 Top 2 Doses Pooled13.64
Modafinil 200 mg17.45

Activation-Performance Relationship Between Functional Magnetic Resonance Imaging (fMRI) in Anterior Cingulate Cortex (ACC) and 2-Back Working Memory Test -Blood Oxygen Level Dependent (BOLD) Signal Intensity at Endpoint

With this outcome measure the correlation between the BOLD signal intensity on fMRI in the ACC versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline

InterventionCorrelation Coefficient (Number)
Armodafinil0.025
Placebo-0.012

Activation-Performance Relationship Between Functional Magnetic Resonance Imaging (fMRI) in Posterior Parietal Cortex (PPC) and the 2-Back Working Memory Test -Number of Voxels Activated at Endpoint

With this outcome measure the correlation between the number of voxels activated on fMRI (voxels that differ significantly from reference wave form) in PPC versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline

InterventionCorrelation Coefficient (Number)
Armodafinil0.355
Placebo-0.358

Activation-Performance Relationship Between Functional Magnetic Resonance Imaging (fMRI) in the Thalamus and 2-Back Working Memory Test -Number of Voxels Activated at Endpoint

With this outcome measure the correlation between the number of voxels activated on fMRI (voxels that differ significantly from reference wave form) in the thalamus versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline

InterventionCorrelation Coefficient (Number)
Armodafinil0.405
Placebo-0.038

Activation-Performance Relationship Between the Functional Magnetic Resonance Imaging (fMRI) in Anterior Cingulate Cortex (ACC) and 2-Back Working Memory Test - Number of Voxels Activated at Endpoint

With this outcome measure the correlation between the number of voxels activated on fMRI (voxels that differ significantly from reference wave form) in ACC versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline

InterventionCorrelation Coefficient (Number)
Armodafinil0.254
Placebo-0.152

Activation-Performance Relationship Between the Functional Magnetic Resonance Imaging (fMRI) in Dorsolateral Prefrontal Cortex (DLPFC) and 2-Back Working Memory Test - Blood Oxygen Level Dependent (BOLD) Signal Intensity at Endpoint

With this outcome measure the correlation between the BOLD signal intensity on fMRI over DLPFC versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline

InterventionCorrelation Coefficient (Number)
Armodafinil-0.122
Placebo0.789

Activation-Performance Relationship Between the Functional Magnetic Resonance Imaging (fMRI) in Dorsolateral Prefrontal Cortex (DLPFC) and 2-Back Working Memory Test - Number of Voxels Activated at Endpoint

With this outcome measure the correlation between the number of voxels activated on fMRI (voxels that differ significantly from reference wave form) in DLPFC versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Endpoint (Week 2 or last observation after baseline)

InterventionCorrelation Coefficient (Number)
Armodafinil0.422
Placebo-0.445

Activation-Performance Relationship on Functional Magnetic Resonance Imaging (fMRI) in Posterior Parietal Cortex (PPC) and 2-Back Working Memory Test - Blood Oxygen Level Dependent (BOLD) Signal Intensity at Endpoint

With this outcome measure the correlation between the BOLD signal intensity on fMRI in PPC versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline

InterventionCorrelation Coefficient (Number)
Armodafinil0.065
Placebo0.364

Activation-Performance Relationship on Functional Magnetic Resonance Imaging (fMRI) in the Thalamus and 2-Back Working Memory Test - Blood Oxygen Level Dependent (BOLD) Signal Intensity at Endpoint

With this outcome measure the correlation between BOLD signal intensity on fMRI in the thalamus versus performance on the 2-back working memory test was evaluated for both Armodafinil and Placebo. Correlation coefficients and P-values are presented for each treatment group. (NCT00711516)
Timeframe: Week 2 or Last Observation after Baseline

InterventionCorrelation Coefficient (Number)
Armodafinil-0.029
Placebo0.582

Blood Oxygenation Level Dependent (BOLD) Signal Intensity - Percent Change From Baseline to Endpoint in the Anterior Cingulate Cortex (ACC)

Functional magnetic resonance imaging (fMRI) is a brain imaging technique that identifies neuronal activation in regions related to specific tasks or sensory stimulation such as language, vision, hearing, and short-term memory. When neuronal activity increases, blood flow increases to that part of the brain with an increase in the oxygen content of the blood. Increase in oxygen content causes the fMRI signal in that part of the brain to change, and is the basis of the BOLD effect. The percent change in BOLD signal from Baseline to 2 weeks or last observation after baseline is presented here. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionPercent change in BOLD signal (Median)
Armodafinil-1.777
Placebo7.148

Blood Oxygenation Level Dependent (BOLD) Signal Intensity - Percent Change From Baseline to Endpoint in the Dorsolateral Prefrontal Cortex (DLPFC)

Functional magnetic resonance imaging (fMRI) is a brain imaging technique that identifies neuronal activation in regions related to specific tasks or sensory stimulation such as language, vision, hearing, and short-term memory. When neuronal activity increases, blood flow increases to that part of the brain with an increase in the oxygen content of the blood. Increase in oxygen content causes the fMRI signal in that part of the brain to change, and is the basis of the BOLD effect. The percent change in BOLD signal from Baseline to 2 weeks or last observation after baseline is presented here. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionPercentage change in BOLD signal (Median)
Armodafinil-0.398
Placebo4.704

Blood Oxygenation Level Dependent (BOLD) Signal Intensity - Percent Change From Baseline to Endpoint in the Thalamus

Functional magnetic resonance imaging (fMRI) is a brain imaging technique that identifies neuronal activation in regions related to specific tasks or sensory stimulation such as language, vision, hearing, and short-term memory. When neuronal activity increases, blood flow increases to that part of the brain with an increase in the oxygen content of the blood. Increase in oxygen content causes the fMRI signal in that part of the brain to change, and is the basis of the BOLD effect. The percent change in BOLD signal from Baseline to 2 weeks or last observation after baseline is presented here. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionPercent change in BOLD signal (Median)
Armodafinil16.363
Placebo2.099

Blood Oxygenation Level Dependent (BOLD) Signal Intensity -Change From Baseline to Endpoint in the Posterior Parietal Cortex (PPC)

Functional magnetic resonance imaging (fMRI) is a brain imaging technique that identifies neuronal activation in regions related to specific tasks or sensory stimulation such as language, vision, hearing, and short-term memory. When neuronal activity increases, blood flow increases to that part of the brain with an increase in the oxygen content of the blood. Increase in oxygen content causes the fMRI signal in that part of the brain to change, and is the basis of the BOLD effect. The percent change in BOLD signal from Baseline to 2 weeks or last observation after baseline is presented here. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionPercent change in Bold signal (Median)
Armodafinil3.199
Placebo-2.021

Change From Baseline in the BOLD Signal Intensity in the Posterior Parietal Cortex (PPC) at Resting State

At resting state, this is an analysis of the change from Baseline to Endpoint in the blood oxygen level dependent (BOLD) signal intensity in the posterior parietal cortex (PPC). (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionBOLD signal intensity (Median)
Armodafinil2.667
Placebo2.479

Change From Baseline to Endpoint (2 Weeks or Last Observation After Baseline) in the Mean Response Latency in the Psychomotor Vigilance-Like Test

"During anatomic scanning (and prior to functional runs when anatomic scanning was not performed), a modified continuous 10 minute attention task (Psychomotor Vigilance Test [PVT]-like task, nearly identical to the PVT but for absence of performance feedback) was run to obtain a measure of vigilance in the scanner-in this instance, the + symbol appeared at random (mean inter trial interval of 5 seconds, range 2 - 10 seconds) but disappeared when subject pressed a button. Subject performance speed was measured. Change in subject performance speed from Baseline to Endpoint is presented." (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after Baseline)

Interventionmilliseconds (ms) (Least Squares Mean)
Armodafinil-31.9
Placebo-6.8

Change From Baseline to Endpoint in Mean Response Latency in the 2-Back Working Memory Test at Endpoint - Mean Performance Speed

The 2-Back is a verbal working memory test in which random letters are presented visually every 4 sec, with each stimulus lasting 500 msec. Subjects are asked to make a yes/no response following each letter indicating whether it was the same or different from the letter presented two earlier. The load on working memory was the ordering, retention, updating, and manipulation of 2 letters and consideration of the relationship to a 3rd newly presented letter, which could have been a target or a nontarget. The change from baseline in response latency at endpoint is presented here. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionMilliseconds (ms) (Mean)
Armodafinil2.3
Placebo-59.0

Change From Baseline to Endpoint in Number of Contiguous Activated Voxels Meeting Predefined Threshold in Dorsolateral Prefrontal Cortex (DLPFC) on Functional Magnetic Resonance Imaging (fMRI) as a Measure of Prefrontal Cortical Activation

The primary outcome was the change from baseline in number of contiguous activated voxels in the dorsolateral prefrontal cortex (DLPFC) on functional magnetic resonance imaging (fMRI) at Week 2(or last observation after baseline). Each voxel is compared to the reference wave form. If it differs from that value p<0.05, the voxel is considered active. fMRI is a brain imaging technique that identifies neuronal activation related to specific tasks or sensory stimulation. Increased neuronal activity increases blood flow and oxygen content to the activated part of the brain, altering fMRI signal. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionActivated voxels (Mean)
Armodafinil-1932.3
Placebo-2428.1

Change From Baseline to Endpoint in the BOLD Signal Intensity in the Anterior Cingulate Cortex (ACC) at Resting State

At resting state, this is an analysis of the change from Baseline to Endpoint in the blood oxygen level dependent signal (BOLD) intensity in the anterior cingulate cortex (ACC). (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after Baseline)

InterventionBOLD signal intensity (Median)
Armodafinil2.778
Placebo0.0

Change From Baseline to Endpoint in the BOLD Signal Intensity in the Dorsolateral Prefrontal Cortex (DLPFC) at Resting State

At resting state, this is an analysis of the change from Baseline to Endpoint in the blood oxygen level dependent (BOLD) signal intensity in the dorsolateral prefrontal cortex (DLPFC). (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionBOLD signal intensity (Median)
Armodafinil5.556
Placebo3.755

Change From Baseline to Endpoint in the BOLD Signal Intensity in the Thalamus at Resting State

At resting state, this is an analysis of the change from Baseline to Endpoint in the blood oxygen level dependent (BOLD) signal intensity in the thalamus. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after Baseline)

InterventionBOLD signal intensity (Median)
Armodafinil5.128
Placebo1.429

Change From Baseline to Endpoint in the Number of Contiguous Activated Voxels Meeting the Predefined Threshold in the Anterior Cingulate Cortex (ACC)

The outcome was the change from baseline in number of contiguous activated voxels in the anterior cingulate cortex (ACC) on functional magnetic resonance imaging (fMRI) at Week 2(or last observation after baseline). Each voxel is compared to the reference wave form. If it differs from that value p<0.05, the voxel is considered active. fMRI is a brain imaging technique that identifies neuronal activation related to specific tasks or sensory stimulation. Increased neuronal activity increases blood flow and oxygen content to the activated part of the brain, altering fMRI signal. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionActivated Voxels (Mean)
Armodafinil-107.3
Placebo-206.5

Change From Baseline to Endpoint in the Number of Contiguous Activated Voxels Meeting the Predefined Threshold in the Thalamus

The outcome was the change from baseline in number of contiguous activated voxels in the thalamus on functional magnetic resonance imaging (fMRI) at Week 2(or last observation after baseline). Each voxel is compared to the reference wave form. If it differs from that value significantly (p<0.05), the voxel is considered active. fMRI is a brain imaging technique that identifies neuronal activation related to specific tasks or sensory stimulation. Increased neuronal activity increases blood flow and oxygen content to the activated part of the brain, altering fMRI signal. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionActivated voxels (Mean)
Armodafinil-841.7
Placebo-1417.9

Change From Baseline to Endpoint in the Number of Contiguous Voxels Meeting the Predefined Threshold in the Posterior Parietal Cortex (PPC)

The outcome was the change from baseline in number of contiguous activated voxels in the posterior parietal cortex (PPC) on functional magnetic resonance imaging (fMRI) at Week 2(or last observation after baseline). Each voxel is compared to the reference wave form. If it differs from that value with p<0.05, the voxel is considered active. fMRI is a brain imaging technique that identifies neuronal activation related to specific tasks or sensory stimulation. Increased neuronal activity increases blood flow and oxygen content to the activated part of the brain, altering fMRI signal. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionActivated voxels (Mean)
Armodafinil-595.0
Placebo-773.3

Change From Baseline to Endpoint in the Number of Voxels Meeting Predefined Threshold in Anterior Cingulate Cortex (ACC) at Resting State

At resting state, this is an analysis of the change from Baseline to Endpoint in the number of contiguous activated voxels meeting pre-defined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI) in the anterior cingulate cortex (ACC). (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after Baseline)

InterventionVoxels (Median)
Armodafinil-27.5
Placebo-54.0

Change From Baseline to Endpoint in the Number of Voxels Meeting Predefined Threshold in Posterior Parietal Cortex (PPC) at Resting State

At resting state, this is an analysis of the change from Baseline to Endpoint in the number of activated voxels meeting predefined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI) in the posterior parietal cortex (PPC). (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after Baseline)

InterventionVoxels (Median)
Armodafinil22.0
Placebo104.3

Change From Baseline to Endpoint in the Number of Voxels Meeting Predefined Threshold in the Dorsolateral Prefrontal Cortex (DLPFC) at Resting State

At resting state, this is an analysis of the change from Baseline to Endpoint in the number of contiguous activated voxels (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI) in the dorsolateral prefrontal cortex. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionVoxels (Median)
Armodafinil941.5
Placebo-174.5

Change From Baseline to Endpoint in the Number of Voxels Meeting Predefined Threshold in the Thalamus at Resting State

At resting state, this is an analysis of the change from Baseline to Endpoint in the number of activated voxels meeting predefined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI) in the thalamus. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionVoxels (Median)
Armodafinil-621.0
Placebo-883.8

Clinical Global Impression of Change (CGI-C)- Number of Responders at Endpoint

Severity of sleepiness, was assessed by the Clinical Global Impression of Severity (CGI-S) at Baseline. The clinician assessed the change from baseline in the patient's condition, as related to excessive sleepiness, in response to treatment using the CGI-C, which consisted of the following 7 categories and scoring assignments: very much improved, much improved, minimally improved, no change, minimally worse, much worse, and very much worse. Responders had to be at least minimally improved from Baseline to qualify as a responder at Endpoint. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionParticipants (Number)
Armodafinil13
Placebo9

Epworth Sleepiness Scale Change From Baseline to Endpoint

The patient's evaluation of excessive daytime sleepiness was measured by the patient reported measure, ESS (Johns1991). The ESS score was based on responses to questions referring to 8 everyday situations (eg, sitting and reading, talking to someone, being stopped in traffic) and reflected a patient's propensity to fall asleep in those situations. The ESS score was derived from the sum of the values from questions corresponding to the 8 situations. Scores for the ESS ranged from 0 to 24, with a higher score indicating a greater daytime sleepiness. Change from baseline to endpoint is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil-5.8
Placebo-2.9

Number of Contiguous Activated Voxels Meeting Predefined Threshold in the ACC on fMRI by 2-Back Working Memory Test -Change From Baseline; Subgroup-Responders in 2 Back Memory Test

This is a subgroup analysis of responders on the 2-back working memory test for the number of activated voxels (that differ significantly from reference wave form) in Anterior Cingulate Cortex (ACC). A responder in the 2-back working memory test was defined as a patient showing a response latency of less than 713 ms at endpoint. This is based on baseline data from the matched control population in a functional imaging study in patients with obstructive sleep apnea. The change from Baseline to Endpoint in the number of activated voxels for each treatment group among the responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionVoxels (Mean)
Armodafinil-38.6
Placebo-227.8

Number of Contiguous Activated Voxels Meeting Predefined Threshold in the ACC on fMRI by 2-Back Working Memory Test-Change From Baseline; Subgroup-Non Responders in 2 Back Memory Test

This is a subgroup analysis of non-responders on the 2-back working memory test for the number of voxels meeting the predefined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI). A non-responder in the 2-back working memory test was defined as a patient showing a response latency of 713 ms or greater at endpoint. The change from Baseline to Endpoint in the number of activated voxels in the anterior cingulate cortex (ACC)for each treatment group among the non-responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionVoxels (Mean)
Armodafinil-153.1
Placebo-199.4

Number of Contiguous Activated Voxels Meeting Predefined Threshold in the DLPFC on fMRI by 2-Back Working Memory Test-Change From Baseline; Subgroup-Non Responders in 2 Back Memory Test

This is a subgroup analysis of non-responders on the 2-back working memory test for the number of voxels meeting the predefined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI). A non-responder in the 2-back working memory test was defined as a patient showing a response latency of 713 ms or greater at endpoint. The change from Baseline to Endpoint in the number of activated voxels in the dorsolateral prefrontal cortex (DLPFC)for each treatment group among the non-responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionVoxels (Mean)
Armodafinil-2279.4
Placebo-2784.4

Number of Contiguous Activated Voxels Meeting Predefined Threshold in the DLPFC on fMRI on the 2 Back Working Memory Test - Change From Baseline-Subgroup-Responders in 2 Back Working Memory Test

This is a subgroup analysis of responders on the 2-back working memory test for the number of voxels meeting the predefined threshold in DLPFC. A responder in the 2-back working memory test was defined as a patient showing a response latency of less than 713 ms at endpoint. This is based on baseline data from the matched control population in a functional imaging study in patients with obstructive sleep apnea. The change from Baseline to Endpoint in the number of activated voxels (that differ significantly from reference wave form) for each treatment group among the responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionActivated voxels (Mean)
Armodafinil-1411.6
Placebo-1359.0

Number of Contiguous Activated Voxels Meeting Predefined Threshold in the PPC on fMRI by 2-Back Working Memory Test-Change From Baseline; Subgroup-Non Responders in 2 Back Memory Test

This is a subgroup analysis of non-responders on the 2-back working memory test for the number of voxels meeting the predefined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI). A non-responder in the 2-back working memory test was defined as a patient showing a response latency of 713 ms or greater at endpoint. The change from Baseline to Endpoint in the number of activated voxels in the posterior parietal cortex (PPC)for each treatment group among the non-responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionVoxels (Mean)
Armodafinil-465.5
Placebo-898.5

Number of Contiguous Activated Voxels Meeting Predefined Threshold in the PPC on fMRI by 2-Back Working Memory Test-Change From Baseline; Subgroup-Responders in 2 Back Memory Test

This is a subgroup analysis of responders on the 2-back working memory test for the number of voxels (voxels that differ significantly from reference wave form) in Posterior Parietal Cortex (PPC). A responder in the 2-back working memory test was defined as a patient showing a response latency of less than 713 ms at endpoint. This is based on baseline data from the matched control population in a functional imaging study in patients with obstructive sleep apnea. The change from Baseline to Endpoint in the number of activated voxels for each treatment group among the responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionVoxels (Mean)
Armodafinil-789.1
Placebo-397.7

Number of Contiguous Activated Voxels Meeting Predefined Threshold in the Thalamus on fMRI by 2-Back Working Memory Test-Change From Baseline; Subgroup-Non Responders in 2 Back Memory Test

This is a subgroup analysis of non-responders on the 2-back working memory test for the number of voxels meeting the predefined threshold (voxels that differ significantly from reference wave form) on functional magnetic resonance imaging (fMRI). A non-responder in the 2-back working memory test was defined as a patient showing a response latency of 713 ms or greater at endpoint. The change from Baseline to Endpoint in the number of activated voxels in the thalamus for each treatment group among the non-responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionVoxels (Mean)
Armodafinil-893.1
Placebo-1408.3

Number of Contiguous Activated Voxels Meeting Predefined Threshold in the Thalamus on fMRI by 2-Back Working Memory Test-Change From Baseline; Subgroup-Responders in 2 Back Memory Test

This is a subgroup analysis of responders on the 2-back working memory test for the number of activated voxels (voxels that differ significantly from reference wave form) in the thalamus. A responder in the 2-back working memory test was defined as a patient showing a response latency of less than 713 ms at endpoint. This is based on baseline data from the matched control population in a functional imaging study in patients with obstructive sleep apnea. The change from Baseline to Endpoint in the number of activated voxels for each treatment group among the responders is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionVoxels (Mean)
Armodafinil-764.7
Placebo-1446.7

One Touch Stockings of Cambridge (OTS) Mean Choices to Correct, (Easy) From the CANTAB Battery-Change From Baseline to Endpoint

OTS is a spatial planning test based on the Tower of London and the CANTAB Stockings of Cambridge test, and measures frontal lobe function. Patient shown 2 displays containing 3 colored balls and a row of boxes containing numbers. The patient is shown one demonstration problem and then solves 3 additional problems (easy). Problems increased in complexity, from one to six moves. With additional problems (hard) the patient has to work out how many moves the solutions required in their heads. Mean change from Baseline to endpoint in number of choices to correct for easy problems is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionChoices to correct (Mean)
Armodafinil0.0
Placebo0.0

One Touch Stockings of Cambridge (OTS) Mean Choices to Correct, (Hard) From the CANTAB Battery-Change From Baseline to Endpoint

OTS is a spatial planning test based on the Tower of London and the CANTAB Stockings of Cambridge test, and measures frontal lobe function. Patient shown 2 displays containing 3 colored balls and a row of boxes containing numbers. The patient was shown one demonstration problem and then solves 3 additional problems (easy). Problems increased in complexity, from one to six moves. With additional problems (hard) the patient had to work out how many moves the solutions required in their heads. Mean change from baseline to endpoint in number of choices to correct for hard problems is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionChoices to correct (Mean)
Armodafinil-0.2
Placebo0.0

One Touch Stockings of Cambridge (OTS) Mean Correct Latency, (Easy) From the CANTAB Battery-Change From Baseline to Endpoint

OTS is a spatial planning test based on Tower of London test and the CANTAB Stockings of Cambridge test, and measures frontal lobe function. Subject is shown 2 displays containing 3 colored balls and a row of boxes containing numbers. The patient was shown one demonstration problem and then had to solve 3 additional problems (easy). The problems increased in complexity, from one to six moves. With additional problems subject had to work out how many moves the solutions required in their heads (hard). Change from baseline to endpoint in Mean correct latency for the easy problems is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionMilliseconds (ms) (Mean)
Armodafinil-787.9
Placebo-666.7

One Touch Stockings of Cambridge (OTS) Mean Correct Latency, (Hard) From the CANTAB Battery-Change From Baseline to Endpoint

OTS is a spatial planning test based on Tower of London test and the CANTAB Stockings of Cambridge test, and measures frontal lobe function. Subject is shown 2 displays containing 3 colored balls and a row of boxes containing numbers. The patient was shown one demonstration problem and then had to solve 3 additional problems (easy). The problems increased in complexity, from one to six moves. With additional problems subject had to work out how many moves the solutions required in their heads (hard). Change from baseline to endpoint in Mean correct latency for the hard problems is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionMilliseconds (ms) (Mean)
Armodafinil-733.3
Placebo-6898.1

Pattern Recognition Memory (PRM) Percent Correct (Delayed) From the CANTAB Battery-Change From Baseline to Endpoint

"The PRM test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) assesses episodic memory as measured by a patient's ability to encode and recognize visual information. Patterns appear sequentially on the screen, and patients are instructed to remember them. Twenty minutes following the immediate recognition test, another delayed recognition test is performed, featuring the same stimuli as in the first phase. The change from baseline to endpoint in percent correct responses of this delayed test are presented here. Subjects complete 24 trials per assessment." (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionPercent correct trials (Mean)
Armodafinil0.4
Placebo-1.1

Pattern Recognition Memory (PRM) Percent Correct (Immediate) From the CANTAB Battery-Change From Baseline to Endpoint

The PRM test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) assesses episodic memory by a patient's ability to encode and recognize visual information. Patterns appear sequentially on the screen, and patients are instructed to remember them. Immediately afterwards a recognition test is performed, in which each pattern shown earlier is presented with another pattern of similar form and color. Patient has to touch the pattern seen earlier. Change from baseline to endpoint in % correct responses with immediate recall is presented. Subjects complete 24 trials per assessment. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionPercent correct trials (Mean)
Armodafinil-0.1
Placebo3.2

Reaction Time Index (RTI) Median Correct Latency, Five Choice Test From the CANTAB Battery-Change From Baseline to Endpoint

The RTI is a measure of simple and choice reaction time, movement time and spatio-temporal vigilance during simple and 5 choice reaction time trials. This task also permits measurement of anticipatory/premature responding and perseverative responding. The patient responded to a yellow spot appearing on the screen by letting go of the press pad and touching the location in which the spot appeared. The yellow spot appeared in any 1 of 5 locations in the 5 choice reaction time phase. The change from baseline to endpoint in median correct latency is presented. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionMilliseconds (ms) (Median)
Armodafinil-6.5
Placebo-12.5

Reaction Time Index (RTI) Median Correct Latency, One Choice Test From the CANTAB Battery-Change From Baseline to Endpoint

The RTI is a measure of simple and choice reaction time, movement time and spatio-temporal vigilance during simple and 5 choice reaction time trials. This task also permits measurement of anticipatory/premature responding and perseverative responding. The patient responded to a yellow spot appearing on the screen by letting go of the press pad and touching the location in which the spot appeared. The yellow spot appeared in a single location during the simple reaction time phase. The change from baseline to endpoint in median correct latency is presented here. (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionMilliseconds (ms) (Median)
Armodafinil-13.5
Placebo-4.5

Total Score From the Medical Outcomes Study 6-Item Cognitive Function Scale (MOS-CF6)-Change From Baseline to Endpoint

"The MOS-CF6 is an instrument to assess patient self-reported cognitive function. Items were selected to cover 6 relevant aspects of cognitive functioning as follows: confusion, concentration/thinking, attention, memory, reasoning, problem solving, and processing speed. The CF 6 item responses include 6 choices, ranging from none of the time to all of the time. The CF-6 was scored by summing responses across the 6 items and converting the total to a 0 to 100 point scale, with higher scores indicating better cognitive functioning. Change in MOS-CF6 from baseline to endpoint is reported." (NCT00711516)
Timeframe: Baseline and Endpoint (Week 2 or last observation after baseline)

InterventionUnits on a scale (Least Squares Mean)
Armodafinil6.1
Placebo-0.2

Length of Time From Extubation to Discharge From Postanesthesia Recovery Unit

Length of time of above compared between groups (NCT02494102)
Timeframe: 24 hours

Interventionminutes (Mean)
Placebo53.5
Modafinil61.0

Postanesthesia Quality Recovery Scale Score

Postanesthesia quality recovery scale (PQRS). Component and aggregate scoring on the scale. Measures physiology, nociceptive, emotional activities of daily living cognitive and overall patient perspective. The scale is dimensionless and the aggregate of all individually tested dimensions is scaled from 17-65. A higher value implies improved postanesthesia recovery. Mean difference was assessed in each patient and aggregated thus patients with no difference between pre- and post-operative scores were zeroed (received a zero score if the difference was zero). A negative value was associated with worse outcome. (NCT02494102)
Timeframe: baseline and 6 hours after surgery

Interventionunits on a scale (Mean)
Placebo-5.67
Modafinil-8.91

Reviews

21 reviews available for modafinil and Apnea, Obstructive Sleep

ArticleYear
Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis.
    Annals of internal medicine, 2023, Volume: 176, Issue:5

    Topics: Autoreceptors; Disorders of Excessive Somnolence; Humans; Modafinil; Network Meta-Analysis; Sleep Ap

2023
Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects.
    Substance abuse, 2020, Volume: 41, Issue:2

    Topics: Anxiety; Diarrhea; Drug Eruptions; Drug Interactions; Erythema Multiforme; Forensic Sciences; Headac

2020
Update on Persistent Excessive Daytime Sleepiness in OSA.
    Chest, 2020, Volume: 158, Issue:2

    Topics: Carbamates; Disorders of Excessive Somnolence; Humans; Modafinil; Phenylalanine; Piperidines; Sleep

2020
Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management.
    Annals of the American Thoracic Society, 2021, Volume: 18, Issue:5

    Topics: Continuous Positive Airway Pressure; Disorders of Excessive Somnolence; Humans; Modafinil; Quality o

2021
Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2021, 12-01, Volume: 17, Issue:12

    Topics: Benzhydryl Compounds; Carbamates; Disorders of Excessive Somnolence; Double-Blind Method; Humans; Mo

2021
On treatment but still sleepy: cause and management of residual sleepiness in obstructive sleep apnea.
    Current opinion in pulmonary medicine, 2013, Volume: 19, Issue:6

    Topics: Benzhydryl Compounds; Continuous Positive Airway Pressure; Depression; Disorders of Excessive Somnol

2013
Effect of Wakefulness-Promoting Agents on Sleepiness in Patients with Sleep Apnea Treated with CPAP: A Meta-Analysis.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2015, Oct-15, Volume: 11, Issue:10

    Topics: Benzhydryl Compounds; Continuous Positive Airway Pressure; Disorders of Excessive Somnolence; Humans

2015
Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis.
    The European respiratory journal, 2016, Volume: 47, Issue:5

    Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure;

2016
Effects of Modafinil and Armodafinil in Patients With Obstructive Sleep Apnea: A Meta-analysis of Randomized Controlled Trials.
    Clinical therapeutics, 2016, Volume: 38, Issue:4

    Topics: Benzhydryl Compounds; Humans; Modafinil; Randomized Controlled Trials as Topic; Sleep; Sleep Apnea,

2016
Armodafinil for excessive daytime sleepiness.
    Drugs of today (Barcelona, Spain : 1998), 2008, Volume: 44, Issue:6

    Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Modafinil; Narcolepsy; Sle

2008
Management of patients with obstructive sleep apnea.
    The Journal of family practice, 2008, Volume: 57, Issue:8 Suppl

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; Fatigu

2008
Optimal treatment of obstructive sleep apnea and excessive sleepiness.
    Advances in therapy, 2009, Volume: 26, Issue:3

    Topics: Age Factors; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pre

2009
Armodafinil.
    CNS drugs, 2009, Volume: 23, Issue:9

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Humans; Modafinil

2009
Pharmacologic approaches for the management of symptoms and cardiovascular consequences of obstructive sleep apnea in adults.
    Sleep & breathing = Schlaf & Atmung, 2010, Volume: 14, Issue:4

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Central Nervous System Stimulants; Combined Modality

2010
Managing excessive daytime sleepiness in adults.
    Drug and therapeutics bulletin, 2004, Volume: 42, Issue:7

    Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Dextroamphetamine; Disorders of Exce

2004
Modafinil: new indications for wake promotion.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:1

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Disorders of Exce

2005
Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder.
    CNS drugs, 2005, Volume: 19, Issue:9

    Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Disorders of Excessive Somnolence;

2005
Medical therapy for obstructive sleep apnea: a review by the Medical Therapy for Obstructive Sleep Apnea Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine.
    Sleep, 2006, Volume: 29, Issue:8

    Topics: Benzhydryl Compounds; Combined Modality Therapy; Continuous Positive Airway Pressure; Evidence-Based

2006
Obstructive sleep apnea, hypertension, and wakefulness-promoting agents.
    Current hypertension reports, 2007, Volume: 9, Issue:4

    Topics: Benzhydryl Compounds; Blood Pressure; Central Nervous System Stimulants; Circadian Rhythm; Heart Rat

2007
Modafinil in the treatment of excessive daytime sleepiness.
    Cleveland Clinic journal of medicine, 2007, Volume: 74, Issue:8

    Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulan

2007
Armodafinil: a new treatment for excessive sleepiness.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:4

    Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Drug and Narcotic Control; Drugs,

2008

Trials

26 trials available for modafinil and Apnea, Obstructive Sleep

ArticleYear
Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA.
    Sleep medicine, 2023, Volume: 107

    Topics: Animals; Anxiety; Cognition; Disease Models, Animal; Disorders of Excessive Somnolence; Male; Mice;

2023
A double blind randomized placebo controlled pilot study of single-dose preoperative modafinil for functional recovery after general anesthesia in patients with obstructive sleep apnea.
    Medicine, 2018, Volume: 97, Issue:39

    Topics: Aged; Airway Extubation; Anesthesia Recovery Period; Anesthesia, General; Benzhydryl Compounds; Bloo

2018
Effects of armodafinil on simulated driving and self-report measures in obstructive sleep apnea patients prior to treatment with continuous positive airway pressure.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2013, May-15, Volume: 9, Issue:5

    Topics: Adult; Automobile Driving; Benzhydryl Compounds; Computer Simulation; Continuous Positive Airway Pre

2013
Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study.
    Sleep medicine, 2013, Volume: 14, Issue:10

    Topics: Adolescent; Adult; Benzhydryl Compounds; Combined Modality Therapy; Continuous Positive Airway Press

2013
Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2013, Aug-15, Volume: 9, Issue:8

    Topics: Adult; Aged; Benzhydryl Compounds; Combined Modality Therapy; Continuous Positive Airway Pressure; D

2013
Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial.
    Thorax, 2014, Volume: 69, Issue:3

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Cross-Over Studies; Disorders of Excessive Somnolence

2014
Effect of armodafinil on cortical activity and working memory in patients with residual excessive sleepiness associated with CPAP-Treated OSA: a multicenter fMRI study.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2014, Feb-15, Volume: 10, Issue:2

    Topics: Adolescent; Adult; Benzhydryl Compounds; Cerebral Cortex; Continuous Positive Airway Pressure; Disor

2014
Modafinil in the treatment of idiopathic hypersomnia without long sleep time--a randomized, double-blind, placebo-controlled study.
    Journal of sleep research, 2015, Volume: 24, Issue:1

    Topics: Adolescent; Adult; Benzhydryl Compounds; Double-Blind Method; Female; Humans; Idiopathic Hypersomnia

2015
Modafinil Increases Awake EEG Activation and Improves Performance in Obstructive Sleep Apnea during Continuous Positive Airway Pressure Withdrawal.
    Sleep, 2015, Aug-01, Volume: 38, Issue:8

    Topics: Attention; Automobile Driving; Benzhydryl Compounds; Biomarkers; Continuous Positive Airway Pressure

2015
A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing.
    Sleep medicine, 2010, Volume: 11, Issue:1

    Topics: Adjuvants, Anesthesia; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Comorbi

2010
Treatment of sleep disorders after traumatic brain injury.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2009, Apr-15, Volume: 5, Issue:2

    Topics: Adult; Benzhydryl Compounds; Benzothiazoles; Brain Injuries; Central Nervous System Stimulants; Diso

2009
A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome.
    Sleep & breathing = Schlaf & Atmung, 2011, Volume: 15, Issue:1

    Topics: Adjuvants, Anesthesia; Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Combined Moda

2011
Modafinil improves functional outcomes in patients with residual excessive sleepiness associated with CPAP treatment.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2009, Dec-15, Volume: 5, Issue:6

    Topics: Activities of Daily Living; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Co

2009
Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2010, Oct-15, Volume: 6, Issue:5

    Topics: Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Female; Follow-Up Studies; Hea

2010
The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2010, Oct-15, Volume: 6, Issue:5

    Topics: Adult; Benzhydryl Compounds; Blood Pressure; Central Nervous System Stimulants; Double-Blind Method;

2010
Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study.
    Clinical therapeutics, 2010, Volume: 32, Issue:12

    Topics: Area Under Curve; Benzhydryl Compounds; Central Nervous System Stimulants; Cross-Over Studies; Disor

2010
Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP.
    Sleep medicine, 2003, Volume: 4, Issue:5

    Topics: Adult; Aged; Arousal; Attention; Benzhydryl Compounds; Continuous Positive Airway Pressure; Double-B

2003
Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study.
    Chest, 2003, Volume: 124, Issue:6

    Topics: Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Chemotherapy, Adjuvant; Contin

2003
Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome.
    Sleep, 2005, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positiv

2005
Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
    Clinical therapeutics, 2006, Volume: 28, Issue:5

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; Disord

2006
Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome.
    Respiratory medicine, 2007, Volume: 101, Issue:3

    Topics: Adjuvants, Pharmaceutic; Adult; Aged; Attention; Benzhydryl Compounds; Central Nervous System Stimul

2007
Effect of adjunctive modafinil on wakefulness and quality of life in patients with excessive sleepiness-associated obstructive sleep apnoea/hypopnoea syndrome: a 12-month, open-label extension study.
    CNS drugs, 2007, Volume: 21, Issue:5

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; Double

2007
The 5-min pupillary alertness test is sensitive to modafinil: a placebo controlled study in patients with sleep apnea.
    Psychopharmacology, 2008, Volume: 196, Issue:2

    Topics: Adult; Arousal; Benzhydryl Compounds; Body Mass Index; Central Nervous System Stimulants; Circadian

2008
Placebo and modafinil effect on sleepiness in obstructive sleep apnea.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Feb-15, Volume: 32, Issue:2

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Combined Modality Therapy; Comorbidity; Con

2008
The effect of modafinil following acute CPAP withdrawal: a preliminary study.
    Sleep & breathing = Schlaf & Atmung, 2008, Volume: 12, Issue:4

    Topics: Adult; Arousal; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Posit

2008
Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea.
    American journal of respiratory and critical care medicine, 2001, Nov-01, Volume: 164, Issue:9

    Topics: Adult; Aged; Analysis of Variance; Benzhydryl Compounds; Central Nervous System Stimulants; Combined

2001

Other Studies

15 other studies available for modafinil and Apnea, Obstructive Sleep

ArticleYear
Solriamfetol improves chronic sleep fragmentation-induced increases in sleep propensity and ameliorates explicit memory in male mice.
    Sleep, 2023, 05-10, Volume: 46, Issue:5

    Topics: Animals; Disorders of Excessive Somnolence; Male; Mice; Mice, Inbred C57BL; Modafinil; Sleep; Sleep

2023
Recovery Mimicking "Ideal" CPAP Adherence Does Not Improve Wakefulness or Cognition in Chronic Murine Models of OSA: Effect of Wake-Promoting Agents.
    Archivos de bronconeumologia, 2023, Volume: 59, Issue:12

    Topics: Animals; Cognition; Continuous Positive Airway Pressure; Disease Models, Animal; Disorders of Excess

2023
Stimulants associated with reduced risk of hospitalization for motor vehicle accident injury in patients with obstructive sleep apnea-a nationwide cohort study.
    BMC pulmonary medicine, 2020, Feb-03, Volume: 20, Issue:1

    Topics: Accidents, Traffic; Adult; Aged; Central Nervous System Stimulants; Databases, Factual; Female; Hosp

2020
Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
    Pharmacology research & perspectives, 2021, Volume: 9, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Amphetamine; Animals; Carbamates; Corp

2021
Comparison of the Efficacy, Side Effects, and Cost of Modafinil and Intranasal Mometasone Furoate in Obstructive Sleep Apnea-Hypopnea Syndrome: A Preliminary Clinical Study.
    Medical science monitor : international medical journal of experimental and clinical research, 2018, May-11, Volume: 24

    Topics: Administration, Intranasal; Adult; Benzhydryl Compounds; Female; Humans; Male; Modafinil; Mometasone

2018
Sleepiness and Sleep-related Breathing Disorders in Myotonic Dystrophy and Responses to Treatment: A Prospective Cohort Study.
    Journal of neuromuscular diseases, 2016, 11-29, Volume: 3, Issue:4

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Cohort Studies; Comorbidity; Continuous Positive Airw

2016
Modafinil use in patients with a primary psychiatric illness.
    The Australian and New Zealand journal of psychiatry, 2010, Volume: 44, Issue:6

    Topics: Adult; Affect; Arousal; Benzhydryl Compounds; Bipolar Disorder; Brain Injury, Chronic; Central Nervo

2010
Can any medication relieve sleep apnea?
    The Johns Hopkins medical letter health after 50, 2012, Volume: 24, Issue:3

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Middle Aged; Modafinil; Patient Edu

2012
Modafinil and armodafinil in schizophrenia.
    The Journal of clinical psychiatry, 2012, Volume: 73, Issue:8

    Topics: Antipsychotic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Cytochrome P-450 CYP1

2012
Pro: modafinil has a role in management of sleep apnea.
    American journal of respiratory and critical care medicine, 2003, Jan-15, Volume: 167, Issue:2

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Controlled Clinical Trials as Topic; Female

2003
Narcolepsy drug could be approved for wider use.
    Lancet (London, England), 2003, Oct-04, Volume: 362, Issue:9390

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Drug Approval; Humans; Modafinil; Narcoleps

2003
Modafinil and sleepiness.
    American journal of respiratory and critical care medicine, 2003, Dec-15, Volume: 168, Issue:12

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; Humans

2003
Treatment of patients with obstructive sleep apnea.
    American family physician, 2005, Mar-01, Volume: 71, Issue:5

    Topics: Accidents; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Press

2005
Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea.
    Sleep & breathing = Schlaf & Atmung, 2008, Volume: 12, Issue:1

    Topics: Adult; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition Disorders; Comb

2008
Evaluation of the safety of modafinil for treatment of excessive sleepiness.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2007, Oct-15, Volume: 3, Issue:6

    Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure;

2007